MARINUS PHARMACEUTICALS, INC. reports $34.7 million Q1 loss

MARINUS PHARMACEUTICALS, INC. [MRNS] has reported fiscal Q1 loss of $34.70 million.

On a per-share basis, the DE based company said its diluted earnings are $0.67.

The Pharmaceutical Preparations firm posted revenue of $10.40 million in this period.

Also Read:

• Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
• Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
• Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results